TY - JOUR T1 - Is Pulmonary Medication Adherence affected by disease severity among adult patients with Cystic Fibrosis? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.368 VL - 56 IS - suppl 64 SP - 368 AU - Elpis Hatziagorou AU - Katerina Manika AU - S.S. Kyrvasili AU - E Kouroukli AU - E Sourla AU - I Lialias AU - S.C. Kotoulas AU - M Sionidou AU - J Kioumis AU - J Tsanakas Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/368.abstract N2 - Aim: To evaluate associations of adherence to pulmonary medications with disease severity (FEV1), age and health-care use among adults with CF.Methods: We evaluated 55 adults with CF over 5 years. A 12-month medication possession ratio (MPR) was computed for each pulmonary medication and then averaged for a composite MPR (cMPR) for each patient. The cMPR was categorized as low (> 0.50), moderate (0.50-0.80), or high (> 0.80). FEV1% predicted, BMI, pulmonary complications, days of hospitalization and number of pulmonary exacerbations were recorded.Results: Mean (range) age of the study group was 28.9 (18-61) years, BMI 21.9 (16.3 – 21.6) kg/m2, FEV1% predicted 73.6 (28.5 – 125.0) %, mean days of iv antibiotics per year was 12.0 (0- 36,75). Mean cMPR was 74.6% (35-100). Low cMPR was found among 10.7% of the patients, while moderate and high cMPR was found among 41.1% and 48.2% of the patients, respectively. Adherence was inversely correlated to FEV1% predicted (r2 = 0.274, p<0.05). Adherence was not found to be related to age of the patients, number of inhaled medications, number of pulmonary exacerbations and days of iv antibiotics.Conclusions: High adherence was found among our study group. Worse adherence to pulmonary medications was found among patients with mild disease. It is very important to address the need to comply with the medical instructions and get the inhaled medication from the early stages of the disease, to delay chronic lung infection and lung function deterioration.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 368.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -